GENE ONLINE|News &
Opinion
Blog

2022-09-28|

GC Labs becomes the first Korean laboratory to obtain certification of CDC standardization programs (VDSCP & HoSt)

by GeneOnline
Share To

YONGIN, South Korea and AUSTIN, Texas, Sept. 29, 2022 /PRNewswire/ — GC Labs, a leading South Korea clinical laboratory, today announced that it has recently obtained certification of standardization programs from the U.S. Centers for Disease Control and Prevention (CDC) for vitamin D and hormones (testosterone).

GC Labs becomes the first Korean clinical laboratory to participate in Vitamin D Standardization Certification Program (VDSCP) and the Hormone Standardization Program (HoSt) from the third quarter of 2021, and to be finally certified on July 14, 2022. In particular, the individual samples passing rate of VDSCP and HoSt was 68% and 88% respectively, which are much higher than those of the global top-tier manufacturers and laboratories.

"Special chemistry department in GC Labs is researching and developing various hormones and vitamin D measurements based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) to provide more accurate and precise test results than conventional immunological methods," said Dr. Eun Hee Lee, President of GC Labs. "The acquisition of global standardization certification proves that GC Lab’s test accuracy and reliability are very high and leads to strengthen its global competitiveness."

CDC operates international standardization programs aimed at manufacturers and laboratories to improve the detection and diagnosis of disease by ensuring that laboratory tests are accurate and reliable. The goal of the program is to contribute to improving the health of mankind by ensuring correct diagnoses and treatment of patients and reducing confusion and re-examination due to inaccurate data.

The program has a high level of difficulty for assessment procedures, where participants measure the true value of samples in multiple concentrations for a year and report the results, which would be assessed against the strict criterion. To be certified, participants should meet each performance criterion of ± 6.4 percent mean bias when compared to the true value provided by CDC for testosterone and of ± 5.0 percent mean bias with overall imprecision under 10 percent when compared to the true value provided by CDC for vitamin D during four consecutive quarters.

About GC Labs

GC Labs is South Korea’s leading clinical laboratory that also specializes in infectious diseases and serves as part of the Global Diagnostics Network. GC Labs has enabled patients to receive an accurate diagnosis and the right treatment with unrivalled quality of routine and specialized clinical tests. Around 800 employees at GC Labs offer more than 5,000 tests and test combinations, ranging from routine tests to highly esoteric molecular and genetic assays.

With more than 40 years of accumulated know-how, GC Labs values the principles of providing the best treatment for patients even in unpredictable medical environments through passionate and ceaseless efforts. Not only domestically, but also GC Labs has managed to expand overseas by entering a Lab Service Agreement with 20 institutions across 15 countries worldwide. GC Labs is qualified with world-class medical standards of medical manpower, level and infrastructure.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Lunit AI Solutions to Power Samsung’s X-ray Devices for Advanced Chest Screening
2024-01-16
FDA Keynote Speaker in the Spotlight, CAR-T Industry Leaders Gather for Discussion-Join the 2024 GenScript Biotech Global Forum for a New Journey in Cell and Gene Therapy
2023-12-24
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications
2023-12-17
LATEST
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Join Us for the SABPA OC/LA 16th Annual Biomedical Forum!
2024-04-16
Sequencing Revolution Spotlights the Titans of NGS Innovation
2024-04-16
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top